IN149973B - - Google Patents

Info

Publication number
IN149973B
IN149973B IN19/DEL/81A IN19DE1981A IN149973B IN 149973 B IN149973 B IN 149973B IN 19DE1981 A IN19DE1981 A IN 19DE1981A IN 149973 B IN149973 B IN 149973B
Authority
IN
India
Application number
IN19/DEL/81A
Other languages
English (en)
Inventor
S Campbell
J Danilewicz
A Evans
A Ham
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to IN19/DEL/81A priority Critical patent/IN149973B/en
Publication of IN149973B publication Critical patent/IN149973B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN19/DEL/81A 1977-06-03 1981-01-13 IN149973B (enExample)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN19/DEL/81A IN149973B (enExample) 1977-06-03 1981-01-13

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2358277 1977-06-03
IN364/DEL/78A IN148482B (enExample) 1977-06-03 1978-05-15
IN19/DEL/81A IN149973B (enExample) 1977-06-03 1981-01-13

Publications (1)

Publication Number Publication Date
IN149973B true IN149973B (enExample) 1982-06-19

Family

ID=10198020

Family Applications (3)

Application Number Title Priority Date Filing Date
IN364/DEL/78A IN148482B (enExample) 1977-06-03 1978-05-15
IN368/DEL/80A IN149550B (enExample) 1977-06-03 1980-05-20
IN19/DEL/81A IN149973B (enExample) 1977-06-03 1981-01-13

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IN364/DEL/78A IN148482B (enExample) 1977-06-03 1978-05-15
IN368/DEL/80A IN149550B (enExample) 1977-06-03 1980-05-20

Country Status (29)

Country Link
US (1) US4289772A (enExample)
JP (1) JPS5416488A (enExample)
AR (2) AR222013A1 (enExample)
AT (2) AT362792B (enExample)
AU (1) AU505373B1 (enExample)
BE (1) BE867727A (enExample)
CA (1) CA1111850A (enExample)
DD (1) DD137355A5 (enExample)
DE (1) DE2824064A1 (enExample)
DK (1) DK248078A (enExample)
EG (1) EG13527A (enExample)
ES (4) ES470470A1 (enExample)
FI (1) FI781753A7 (enExample)
FR (1) FR2392986A1 (enExample)
GB (1) GB2000136B (enExample)
GR (1) GR74402B (enExample)
HU (1) HU179745B (enExample)
IL (1) IL54842A (enExample)
IN (3) IN148482B (enExample)
IT (1) IT1094944B (enExample)
LU (1) LU79761A1 (enExample)
NL (1) NL7806016A (enExample)
NO (1) NO781935L (enExample)
NZ (1) NZ187453A (enExample)
PL (3) PL113208B1 (enExample)
PT (1) PT68126A (enExample)
SE (1) SE7806519L (enExample)
SU (2) SU856383A3 (enExample)
ZA (1) ZA783183B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370328A (en) * 1977-11-03 1983-01-25 Pfizer Inc. Cardiac stimulant 1-(3- or 4-substituted piperidino)phthalazines
IL59619A0 (en) * 1979-03-28 1980-06-30 Pfizer Phthalazine derivatives,their preparation and pharmaceutical compositions containing them
PL135545B1 (en) * 1980-03-01 1985-11-30 Wyeth John & Brother Ltd Process for preparing novel derivatives of piperidine
GB8320958D0 (en) * 1983-08-03 1983-09-07 Pfizer Ltd Quinazoline cardiac stimulants
US5001125A (en) * 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4882354A (en) * 1987-12-16 1989-11-21 Norwich Eaton Pharmaceuticals, Inc. N-hydroxy-5-phenyl-2-furancarboximidamides useful as cardiotonic agents
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5300515A (en) * 1991-01-31 1994-04-05 Kyorin Pharmaceutical Co., Ltd. Carbamic acid derivatives and method for preparing the same
EP0621267A1 (en) * 1993-04-07 1994-10-26 Shell Internationale Researchmaatschappij B.V. Spiropiperidine derivatives and their use as fungicides
US5728712A (en) * 1995-05-19 1998-03-17 Chiroscience Limited 3,4-disubstituted-phenylsulphonamides and their therapeutic use
KR100485249B1 (ko) * 1996-08-20 2005-09-09 에자이 가부시키가이샤 축합피리다진계화합물의발기기능부전증치료제
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
EP1539739B1 (en) * 2002-08-16 2010-11-24 Janssen Pharmaceutica NV Piperidinyl compounds that selectively bind integrins
US20060019975A1 (en) * 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
EP2275096A3 (en) 2005-08-26 2011-07-13 Braincells, Inc. Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100222353A1 (en) * 2006-01-27 2010-09-02 Pfizer Products Inc. Aminophthalazine derivative compounds
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007110449A1 (en) 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
EP1903037A1 (de) * 2006-09-07 2008-03-26 Bayer Schering Pharma Aktiengesellschaft 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioharnstoffe als Modulatoren des EP2-Rezeptors
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008124118A1 (en) 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
JP2010535733A (ja) 2007-08-07 2010-11-25 エフ.ホフマン−ラ ロシュ アーゲー Nk3受容体アンタゴニストとしてのピロリジンアリールエーテル
AU2008290634B2 (en) 2007-08-22 2012-12-06 F. Hoffmann-La Roche Ag Pyrrolidine aryl-ether as NK3 receptor antagonists
WO2009033995A1 (en) * 2007-09-14 2009-03-19 F. Hoffmann-La Roche Ag Piperidine derivatives as nk3 receptor antagonists
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP7868066B2 (ja) 2020-10-13 2026-06-01 エンデバー バイオメディシンズ, インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN113087654B (zh) * 2021-04-15 2022-12-23 苏州昊帆生物股份有限公司 哌啶-4-丁胺的制备方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
GB1199768A (en) 1966-10-31 1970-07-22 Pfizer & Co C Nitrogen Heterocycles and process for their preparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
GB1460389A (en) 1974-07-25 1977-01-06 Pfizer Ltd 4-substituted quinazoline cardiac stimulants

Also Published As

Publication number Publication date
ES478200A1 (es) 1980-01-01
EG13527A (en) 1981-12-31
ATA305080A (de) 1980-12-15
SU856383A3 (ru) 1981-08-15
PL116437B1 (en) 1981-06-30
PL207337A1 (pl) 1979-06-04
PL113208B1 (en) 1980-11-29
JPS5538351B2 (enExample) 1980-10-03
NO781935L (no) 1978-12-05
IN148482B (enExample) 1981-03-07
IT7824106A0 (it) 1978-06-01
DE2824064A1 (de) 1978-12-14
PL116420B1 (en) 1981-06-30
ES470470A1 (es) 1979-09-01
GR74402B (enExample) 1984-06-28
DK248078A (da) 1978-12-04
AR222013A1 (es) 1981-04-15
ATA400878A (de) 1980-11-15
IL54842A (en) 1982-01-31
IT1094944B (it) 1985-08-10
US4289772A (en) 1981-09-15
SU862826A3 (ru) 1981-09-07
AT363096B (de) 1981-07-10
IN149550B (enExample) 1982-01-16
IL54842A0 (en) 1978-08-31
AT362792B (de) 1981-06-10
ES478201A1 (es) 1980-02-01
GB2000136A (en) 1979-01-04
AU505373B1 (en) 1979-11-15
CA1111850A (en) 1981-11-03
FR2392986B1 (enExample) 1982-07-16
NL7806016A (nl) 1978-12-05
NZ187453A (en) 1980-12-19
FI781753A7 (fi) 1978-12-04
PT68126A (en) 1978-07-01
ES478199A1 (es) 1980-01-16
BE867727A (fr) 1978-12-01
GB2000136B (en) 1982-01-06
ZA783183B (en) 1979-06-27
LU79761A1 (fr) 1980-01-22
SE7806519L (sv) 1978-12-04
DD137355A5 (de) 1979-08-29
AR223999A1 (es) 1981-10-15
HU179745B (en) 1982-12-28
FR2392986A1 (fr) 1978-12-29
JPS5416488A (en) 1979-02-07

Similar Documents

Publication Publication Date Title
FR2377568B1 (enExample)
FR2376646B1 (enExample)
FR2392986B1 (enExample)
FR2378524B1 (enExample)
FR2376610B1 (enExample)
FR2378071B1 (enExample)
FR2376898B1 (enExample)
DE2803939C2 (enExample)
DE2854286C2 (enExample)
FR2378962B1 (enExample)
FR2378364B1 (enExample)
AR210643A1 (enExample)
AU71461S (enExample)
BG25837A1 (enExample)
BG25828A1 (enExample)
BE865722A (enExample)
BE872973A (enExample)
BG25845A1 (enExample)
BG25819A1 (enExample)
BG25860A1 (enExample)
BG25827A2 (enExample)
BE873002A (enExample)
BG25826A1 (enExample)
BG23462A1 (enExample)
CH605178A5 (enExample)